{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:30Z","timestamp":1792788090066,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012550","name":"National Research, Development and Innovation Fund","doi-asserted-by":"crossref","award":["FK 138929"],"award-info":[{"award-number":["FK 138929"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CF Trust Strategic Research Consortium Grant","award":["NU-000600"],"award-info":[{"award-number":["NU-000600"]}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite widespread vaccination efforts, effective treatment strategies remain critical for severe SARS-CoV-2 infection. Tumour necrosis factor-alpha (TNF-\u03b1) plays a central role in the cytokine storm characteristic of severe COVID-19. This systematic review and meta-analysis evaluates the effectiveness, efficacy, and safety of TNF-\u03b1 inhibitors in the management of COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A systematic review of PubMed, Embase, and CENTRAL was conducted, focusing on studies involving SARS-CoV-2-infected patients treated with TNF-\u03b1 inhibitors compared with those receiving standard of care without prior TNF-\u03b1 inhibitor use. Data from studies published up to August 12, 2024, were analysed. Outcomes assessed included mortality, invasive mechanical ventilation, and C-reactive protein (CRP) levels. Odds ratios (ORs) and mean differences (MD) were calculated with 95% confidence intervals (CI), and subgroup analyses were performed for randomised controlled trials (RCTs) and non-randomised studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven studies involving 1393 patients with moderate-to-critical COVID-19 were included. TNF-\u03b1 inhibitor treatment was associated with a reduced odds of mortality (OR 0.67, 95% CI [0.44\u20131.00],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.052), which was statistically significant in the RCT subgroup across three studies (OR 0.75, 95% CI [0.58\u20130.97],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.042, certainty of evidence: very low). The number needed to treat for mortality was calculated to be 16 (95% CI 9.0-inf.), which indicates that one additional death could be avoided for every 16 patients treated with TNF-\u03b1 inhibitors compared to standard of care. No significant reduction in the need for invasive mechanical ventilation was observed (OR 0.95 [95% CI 0.46\u20131.94];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.822). Additionally, TNF-\u03b1 inhibitors resulted in a significant reduction in CRP levels (MD\u2009\u2212\u200921.9\u00a0mg\/L [95% CI\u2009\u2212\u200938.46 to\u2009\u2212\u20095.34];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.024) within three to seven days post-treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study indicates a potential role for TNF-\u03b1 inhibition in the treatment of COVID-19 as their use was associated with reduced mortality, but further studies are needed to provide robust evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-025-05420-9","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:56:37Z","timestamp":1749203797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumour necrosis factor-alpha inhibitors decrease mortality in COVID-19: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"29","author":[{"given":"\u00c1goston","family":"J\u00e1nosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"B\u00f3dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klementina","family":"Ocskay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"K\u00f3i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibolya","family":"T\u00fari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Garami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"P\u00e1rniczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"1","key":"5420_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.medj.2020.11.005","volume":"1","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Liew DFL, Liew JW, et al. The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med. 2020;1(1):90\u2013102. https:\/\/doi.org\/10.1016\/j.medj.2020.11.005.","journal-title":"Med"},{"issue":"21","key":"5420_CR2","doi-asserted-by":"publisher","first-page":"23895","DOI":"10.18632\/aging.203663","volume":"13","author":"F Jia","year":"2021","unstructured":"Jia F, Wang G, Xu J, Long J, Deng F, Jiang W. Role of tumor necrosis factor-\u03b1 in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia. Aging. 2021;13(21):23895\u2013912. https:\/\/doi.org\/10.18632\/aging.203663.","journal-title":"Aging"},{"issue":"10","key":"5420_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1473-3099(20)30434-5","volume":"20","author":"L Carsana","year":"2020","unstructured":"Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135\u201340. https:\/\/doi.org\/10.1016\/S1473-3099(20)30434-5.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"5420_CR4","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/jcm12041630","volume":"12","author":"GM Leone","year":"2023","unstructured":"Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P. Past, present and (foreseeable) future of biological anti-TNF alpha therapy. J Clin Med. 2023;12(4):1630. https:\/\/doi.org\/10.3390\/jcm12041630.","journal-title":"J Clin Med"},{"issue":"5","key":"5420_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/ph15050616","volume":"15","author":"Y Palacios","year":"2022","unstructured":"Palacios Y, Chavez-Galan L. Immunosuppressant therapies in COVID-19: Is the TNF axis an alternative? Pharmaceuticals. 2022;15(5):616. https:\/\/doi.org\/10.3390\/ph15050616.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"5420_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.clim.2007.08.013","volume":"126","author":"M Wong","year":"2008","unstructured":"Wong M, Ziring D, Korin Y, et al. TNF\u03b1 blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126(2):121\u201336. https:\/\/doi.org\/10.1016\/j.clim.2007.08.013.","journal-title":"Clin Immunol"},{"issue":"10234","key":"5420_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","volume":"395","author":"M Feldmann","year":"2020","unstructured":"Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(20)30858-8.","journal-title":"Lancet"},{"key":"5420_CR8","unstructured":"Gerriets V, Goyal A, Khaddour K. Tumor Necrosis factor inhibitors; 2024. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25985765."},{"issue":"April","key":"5420_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1151764","volume":"14","author":"E Car","year":"2023","unstructured":"Car E, Vulto AG, Van HM, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023;14(April):1\u201315. https:\/\/doi.org\/10.3389\/fphar.2023.1151764.","journal-title":"Front Pharmacol"},{"issue":"10","key":"5420_CR10","doi-asserted-by":"publisher","first-page":"e2129639","DOI":"10.1001\/jamanetworkopen.2021.29639","volume":"4","author":"Z Izadi","year":"2021","unstructured":"Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4(10):e2129639. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.29639.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"5420_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","volume":"80","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137\u201346. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220418.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5420_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","volume":"159","author":"EJ Brenner","year":"2020","unstructured":"Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159(2):481-491.e3. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.032.","journal-title":"Gastroenterology"},{"issue":"7","key":"5420_CR13","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.3390\/ijms24076142","volume":"24","author":"Z Mohd Zawawi","year":"2023","unstructured":"Mohd Zawawi Z, Kalyanasundram J, Mohd Zain R, Thayan R, Basri DF, Yap WB. Prospective roles of tumor necrosis factor-alpha (TNF-\u03b1) in COVID-19: prognosis, therapeutic and management. Int J Mol Sci. 2023;24(7):6142. https:\/\/doi.org\/10.3390\/ijms24076142.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"5420_CR14","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117(21):11727\u201334. https:\/\/doi.org\/10.1073\/pnas.2003138117.","journal-title":"Proc Natl Acad Sci"},{"key":"5420_CR15","unstructured":"National Institutes of Health. Available at https:\/\/www.covid19treatmentguidelines.nih.gov\/. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines; 2024. https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"issue":"10","key":"5420_CR16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636\u201343. https:\/\/doi.org\/10.1038\/s41591-020-1051-9.","journal-title":"Nat Med"},{"key":"5420_CR17","doi-asserted-by":"publisher","first-page":"m1091","DOI":"10.1136\/bmj.m1091","volume":"368","author":"T Chen","year":"2020","unstructured":"Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. https:\/\/doi.org\/10.1136\/bmj.m1091.","journal-title":"BMJ"},{"issue":"10223","key":"5420_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5.","journal-title":"Lancet"},{"key":"5420_CR19","unstructured":"Higgins JPT TJCJCMLTPMWV (editors). Cochrane handbook for systematic reviews of interventions version 6.4\u00a0(Updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook."},{"key":"5420_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"5420_CR21","doi-asserted-by":"publisher","unstructured":"NR Haddaway MGCG. Citationchaser: An R package and Shiny app for forward and backward citations chasing in academic searching. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.4533747.","DOI":"10.5281\/zenodo.4533747"},{"issue":"1","key":"5420_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"issue":"8","key":"5420_CR23","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"JC Marshall","year":"2020","unstructured":"Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192\u20137. https:\/\/doi.org\/10.1016\/S1473-3099(20)30483-7.","journal-title":"Lancet Infect Dis"},{"key":"5420_CR24","doi-asserted-by":"publisher","unstructured":"Ankit Rohatgi SR& Z. ankitrohatgi\/WebPlotDigitizer: Version 4.0 of WebPlotDigitizer (v4.0). Zenodo. https:\/\/doi.org\/10.5281\/zenodo.1039373","DOI":"10.5281\/zenodo.1039373"},{"key":"5420_CR25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"5420_CR26","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu, R Currie M, Qureshi R, Mattis P, Lisy K MPF. Checklist for case control studies. Joanna Briggs Institute Critical Appraisal tools. Published online 2016:1\u20136."},{"key":"5420_CR27","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G OA. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013; 2013. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"key":"5420_CR28","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: a hands-on guide. 1st ed. Chapman & Hall\/CRC Press; 2021.","edition":"1"},{"key":"5420_CR29","unstructured":"Sch\u00fcnemann HJ VGHJSNDJGPAEGG. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook."},{"key":"5420_CR30","unstructured":"Chandler J. Cochrane scientific committee should cochrane apply error-adjustment methods when conducting repeated meta-analyses?"},{"issue":"09\/2023","key":"5420_CR31","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.7754\/Clin.Lab.2023.230343","volume":"69","author":"M Farokhnia","year":"2023","unstructured":"Farokhnia M, Nakhaie M, Shafieipour S, et al. Assessment of the effect of sub-cutaneous adalimumab on prognosis of COVID-19 patients: a non-randomized pilot clinical trial study in Iran. Clin Lab. 2023;69(09\/2023):1962\u20138. https:\/\/doi.org\/10.7754\/Clin.Lab.2023.230343.","journal-title":"Clin Lab"},{"key":"5420_CR32","doi-asserted-by":"publisher","first-page":"107168","DOI":"10.1016\/j.ijid.2024.107168","volume":"146","author":"DY Lin","year":"2024","unstructured":"Lin DY, Wang J, Anstrom KJ, et al. Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumonia. Int J Infect Dis. 2024;146:107168. https:\/\/doi.org\/10.1016\/j.ijid.2024.107168.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"5420_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1001\/jama.2023.11043","volume":"330","author":"JA O\u2019Halloran","year":"2023","unstructured":"O\u2019Halloran JA, Ko ER, Anstrom KJ, et al. Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia. JAMA. 2023;330(4):328. https:\/\/doi.org\/10.1001\/jama.2023.11043.","journal-title":"JAMA"},{"issue":"12","key":"5420_CR34","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1038\/s41375-021-01411-1","volume":"35","author":"PA Reuken","year":"2021","unstructured":"Reuken PA, R\u00fcthrich MM, Hochhaus A, et al. The impact of specific cytokine directed treatment on severe COVID-19. Leukemia. 2021;35(12):3613\u20135. https:\/\/doi.org\/10.1038\/s41375-021-01411-1.","journal-title":"Leukemia"},{"issue":"3","key":"5420_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S2213-2600(21)00460-4","volume":"10","author":"BA Fisher","year":"2022","unstructured":"Fisher BA, Veenith T, Slade D, et al. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir Med. 2022;10(3):255\u201366. https:\/\/doi.org\/10.1016\/S2213-2600(21)00460-4.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"5420_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.34172\/aim.2021.22","volume":"24","author":"M Farrokhpour","year":"2021","unstructured":"Farrokhpour M, Rezaie N, Moradi N, et al. Infliximab and intravenous gammaglobulin in hospitalized severe COVID-19 patients in intensive care unit. Arch Iran Med. 2021;24(2):139\u201343. https:\/\/doi.org\/10.34172\/aim.2021.22.","journal-title":"Arch Iran Med"},{"issue":"107961","key":"5420_CR37","doi-asserted-by":"publisher","first-page":"107961","DOI":"10.1016\/j.intimp.2021.107961","volume":"99","author":"A Fakharian","year":"2021","unstructured":"Fakharian A, Barati S, Mirenayat M, et al. Evaluation of adalimumab effects in managing severe cases of COVID-19: a randomized controlled trial. Int Immunopharmacol. 2021;99(107961):107961. https:\/\/doi.org\/10.1016\/j.intimp.2021.107961.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"5420_CR38","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1038\/s41598-023-33484-6","volume":"13","author":"NM Sarhan","year":"2023","unstructured":"Sarhan NM, Warda AEA, Ibrahim HSG, Schaalan MF, Fathy SM. Evaluation of infliximab\/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome. Sci Rep. 2023;13(1):6456. https:\/\/doi.org\/10.1038\/s41598-023-33484-6.","journal-title":"Sci Rep"},{"issue":"11","key":"5420_CR39","doi-asserted-by":"publisher","first-page":"e742","DOI":"10.1093\/cid\/ciaa1445","volume":"72","author":"J Malgie","year":"2021","unstructured":"Malgie J, Schoones JW, Pijls BG. Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis. 2021;72(11):e742\u20139. https:\/\/doi.org\/10.1093\/cid\/ciaa1445.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"5420_CR40","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/jcm10081607","volume":"10","author":"L Calzetta","year":"2021","unstructured":"Calzetta L, Aiello M, Frizzelli A, Rogliani P, Chetta A. Dexamethasone in patients hospitalized with COVID-19: whether, when and to whom. J Clin Med. 2021;10(8):1607. https:\/\/doi.org\/10.3390\/jcm10081607.","journal-title":"J Clin Med"},{"issue":"15","key":"5420_CR41","doi-asserted-by":"publisher","first-page":"E521","DOI":"10.1503\/cmaj.210066","volume":"193","author":"K Afra","year":"2021","unstructured":"Afra K, Chen LYC, Sweet D. Tocilizumab for hospitalized patients with COVID-19. Can Med Assoc J. 2021;193(15):E521\u2013E521. https:\/\/doi.org\/10.1503\/cmaj.210066.","journal-title":"Can Med Assoc J"},{"issue":"2","key":"5420_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/apt.16717","volume":"55","author":"G Kokkotis","year":"2022","unstructured":"Kokkotis G, Kitsou K, Xynogalas I, et al. Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment Pharmacol Ther. 2022;55(2):154\u201367. https:\/\/doi.org\/10.1111\/apt.16717.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"5420_CR43","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/apt.16872","volume":"55","author":"C Hung","year":"2022","unstructured":"Hung C, Yang T, Wei JC. Letter: COVID-19 outcomes and anti-TNF treatments\u2014comprehensive evidence matters. Aliment Pharmacol Ther. 2022;55(9):1233\u20134. https:\/\/doi.org\/10.1111\/apt.16872.","journal-title":"Aliment Pharmacol Ther"},{"issue":"156006","key":"5420_CR44","doi-asserted-by":"publisher","first-page":"156006","DOI":"10.1016\/j.cyto.2022.156006","volume":"158","author":"AA Gharamti","year":"2022","unstructured":"Gharamti AA, Samara O, Monzon A, et al. Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: a systematic review and meta-analysis. Cytokine. 2022;158(156006):156006. https:\/\/doi.org\/10.1016\/j.cyto.2022.156006.","journal-title":"Cytokine"},{"issue":"10","key":"5420_CR45","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1097\/CCM.0b013e3182982add","volume":"41","author":"P Qiu","year":"2013","unstructured":"Qiu P, Cui X, Sun J, Welsh J, Natanson C, Eichacker PQ. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials. Crit Care Med. 2013;41(10):2419\u201329. https:\/\/doi.org\/10.1097\/CCM.0b013e3182982add.","journal-title":"Crit Care Med"},{"issue":"4","key":"5420_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","volume":"20","author":"JC Marshall","year":"2014","unstructured":"Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195\u2013203. https:\/\/doi.org\/10.1016\/j.molmed.2014.01.007.","journal-title":"Trends Mol Med"},{"issue":"4","key":"5420_CR47","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ijcp.12382","volume":"68","author":"S Lv","year":"2014","unstructured":"Lv S, Han M, Yi R, Kwon S, Dai C, Wang R. Anti-TNF-\u03b1 therapy for patients with sepsis: a systematic meta-analysis. Int J Clin Pract. 2014;68(4):520\u20138. https:\/\/doi.org\/10.1111\/ijcp.12382.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"5420_CR48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.chest.2019.11.019","volume":"158","author":"RA Veldhoen","year":"2020","unstructured":"Veldhoen RA, Howes D, Maslove DM. Is mortality a useful primary end point for critical care trials? Chest. 2020;158(1):206\u201311. https:\/\/doi.org\/10.1016\/j.chest.2019.11.019.","journal-title":"Chest"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05420-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05420-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05420-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:56:39Z","timestamp":1749203799000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-025-05420-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5420"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05420-9","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. No patients were involved in the design, conduct, or interpretation of our study. The datasets used in this study can be found in the full-text articles included in the systematic review and meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}